Clinical Research Directory

Inclusion Criteria: * Age 18-85 years. * Confirmed diagnosis of HCM: 1. Left ventricular wall thickness ≥15 mm at any site on echocardiography or cardiac magnetic resonance. 2. Left ventricular wall thickness ≥13 mm in individuals testing positive for a pathogenic variant or in genetically affected family members. 3. Ventricular wall thickening caused by other cardiovascular diseases or systemic or metabolic disorders has been excluded. * Symptomatic nHCM patients meeting all of the following conditions: 1. Left ventricular outflow tract gradient (LVOTG) \<30 mmHg at rest and/or with provocation. 2. Presence of any one of the following symptoms: fatigue (weakness), dyspnea, chest pain, palpitations, or syncope. 3. New York Heart Association (NYHA) functional class II or III. * Left ventricular ejection fraction (LVEF) ≥60% as assessed by transthoracic echocardiography. * Signed and dated written informed consent, and willingness to return for clinical follow-up. Exclusion Criteria: * LVOTG ≥30 mmHg at rest and/or with provocation. * LVEF \<50% on transthoracic echocardiography. * Symptomatic hypotension or systolic blood pressure (SBP) \<100 mmHg. * Severe renal impairment, estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m², or currently receiving blood purification therapy. * Planned implantable cardioverter-defibrillator (ICD) implantation or cardiac resynchronization therapy (CRT) within 3 months. * Women who are pregnant or planning to become pregnant during the trial. * Currently participating in another investigational device or drug trial. * Any other clinical condition with an expected survival of less than 2 years.